Fluorine in PDB 3g5e: Human Aldose Reductase Complexed with Idd 740 Inhibitor
Enzymatic activity of Human Aldose Reductase Complexed with Idd 740 Inhibitor
All present enzymatic activity of Human Aldose Reductase Complexed with Idd 740 Inhibitor:
1.1.1.21;
Protein crystallography data
The structure of Human Aldose Reductase Complexed with Idd 740 Inhibitor, PDB code: 3g5e
was solved by
A.D.Podjarny,
M.C.Van Zandt,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
13.94 /
1.80
|
Space group
|
P 1 21 1
|
Cell size a, b, c (Å), α, β, γ (°)
|
50.016,
67.204,
47.861,
90.00,
92.58,
90.00
|
R / Rfree (%)
|
14.4 /
18.3
|
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Human Aldose Reductase Complexed with Idd 740 Inhibitor
(pdb code 3g5e). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 3 binding sites of Fluorine where determined in the
Human Aldose Reductase Complexed with Idd 740 Inhibitor, PDB code: 3g5e:
Jump to Fluorine binding site number:
1;
2;
3;
Fluorine binding site 1 out
of 3 in 3g5e
Go back to
Fluorine Binding Sites List in 3g5e
Fluorine binding site 1 out
of 3 in the Human Aldose Reductase Complexed with Idd 740 Inhibitor
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Human Aldose Reductase Complexed with Idd 740 Inhibitor within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F320
b:14.8
occ:1.00
|
F1
|
A:Q74320
|
0.0
|
14.8
|
1.0
|
C2
|
A:Q74320
|
1.4
|
13.1
|
1.0
|
C3
|
A:Q74320
|
2.4
|
12.8
|
1.0
|
C5
|
A:Q74320
|
2.4
|
11.9
|
1.0
|
F4
|
A:Q74320
|
2.8
|
15.8
|
1.0
|
CD1
|
A:TYR309
|
3.4
|
12.7
|
1.0
|
CB
|
A:CYS303
|
3.5
|
16.2
|
1.0
|
C9
|
A:Q74320
|
3.6
|
11.0
|
1.0
|
CG2
|
A:THR113
|
3.7
|
9.6
|
1.0
|
C6
|
A:Q74320
|
3.7
|
11.4
|
1.0
|
CD
|
A:PRO310
|
3.7
|
12.0
|
1.0
|
CE1
|
A:TYR309
|
3.9
|
14.7
|
1.0
|
OG1
|
A:THR113
|
4.0
|
8.9
|
1.0
|
CE3
|
A:TRP111
|
4.1
|
7.4
|
1.0
|
C8
|
A:Q74320
|
4.1
|
10.4
|
1.0
|
SG
|
A:CYS303
|
4.2
|
17.0
|
1.0
|
CZ3
|
A:TRP111
|
4.4
|
7.0
|
1.0
|
CB
|
A:THR113
|
4.4
|
8.8
|
1.0
|
CG
|
A:TYR309
|
4.5
|
13.0
|
1.0
|
CA
|
A:TYR309
|
4.5
|
12.9
|
1.0
|
O
|
A:CYS303
|
4.6
|
15.7
|
1.0
|
CG
|
A:PRO310
|
4.7
|
11.6
|
1.0
|
F7
|
A:Q74320
|
4.7
|
11.4
|
1.0
|
CB
|
A:TYR309
|
4.8
|
12.9
|
1.0
|
CA
|
A:CYS303
|
4.8
|
16.2
|
1.0
|
CD2
|
A:TRP111
|
4.8
|
6.6
|
1.0
|
N10
|
A:Q74320
|
4.8
|
9.5
|
1.0
|
N
|
A:PRO310
|
4.9
|
12.1
|
1.0
|
C
|
A:CYS303
|
4.9
|
15.9
|
1.0
|
|
Fluorine binding site 2 out
of 3 in 3g5e
Go back to
Fluorine Binding Sites List in 3g5e
Fluorine binding site 2 out
of 3 in the Human Aldose Reductase Complexed with Idd 740 Inhibitor
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Human Aldose Reductase Complexed with Idd 740 Inhibitor within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F320
b:15.8
occ:1.00
|
F4
|
A:Q74320
|
0.0
|
15.8
|
1.0
|
C3
|
A:Q74320
|
1.3
|
12.8
|
1.0
|
C9
|
A:Q74320
|
2.3
|
11.0
|
1.0
|
C2
|
A:Q74320
|
2.4
|
13.1
|
1.0
|
F1
|
A:Q74320
|
2.8
|
14.8
|
1.0
|
N10
|
A:Q74320
|
2.8
|
9.5
|
1.0
|
CE1
|
A:TYR309
|
3.4
|
14.7
|
1.0
|
N
|
A:LEU300
|
3.4
|
18.4
|
1.0
|
C8
|
A:Q74320
|
3.6
|
10.4
|
1.0
|
C5
|
A:Q74320
|
3.6
|
11.9
|
1.0
|
CZ3
|
A:TRP111
|
3.7
|
7.0
|
1.0
|
CA
|
A:ALA299
|
3.7
|
16.4
|
1.0
|
CD1
|
A:TYR309
|
4.0
|
12.7
|
1.0
|
C
|
A:ALA299
|
4.0
|
17.8
|
1.0
|
CH2
|
A:TRP111
|
4.1
|
10.3
|
1.0
|
C6
|
A:Q74320
|
4.1
|
11.4
|
1.0
|
C12
|
A:Q74320
|
4.1
|
11.1
|
1.0
|
CE2
|
A:PHE311
|
4.2
|
12.4
|
1.0
|
CB
|
A:CYS303
|
4.2
|
16.2
|
1.0
|
CE3
|
A:TRP111
|
4.3
|
7.4
|
1.0
|
O
|
A:LEU300
|
4.3
|
19.1
|
1.0
|
CB
|
A:LEU300
|
4.3
|
19.3
|
1.0
|
CB
|
A:ALA299
|
4.3
|
16.5
|
1.0
|
CA
|
A:LEU300
|
4.4
|
18.8
|
1.0
|
CZ
|
A:TYR309
|
4.4
|
15.9
|
1.0
|
CD2
|
A:PHE311
|
4.5
|
11.7
|
1.0
|
OH
|
A:TYR309
|
4.6
|
17.7
|
1.0
|
SG
|
A:CYS303
|
4.8
|
17.0
|
1.0
|
N
|
A:ALA299
|
4.8
|
14.4
|
1.0
|
C
|
A:LEU300
|
4.8
|
19.1
|
1.0
|
S11
|
A:Q74320
|
4.9
|
10.6
|
1.0
|
O
|
A:CYS298
|
4.9
|
13.8
|
0.5
|
CZ2
|
A:TRP111
|
4.9
|
9.2
|
1.0
|
O
|
A:CYS298
|
4.9
|
13.0
|
0.5
|
CD
|
A:PRO310
|
5.0
|
12.0
|
1.0
|
|
Fluorine binding site 3 out
of 3 in 3g5e
Go back to
Fluorine Binding Sites List in 3g5e
Fluorine binding site 3 out
of 3 in the Human Aldose Reductase Complexed with Idd 740 Inhibitor
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 3 of Human Aldose Reductase Complexed with Idd 740 Inhibitor within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F320
b:11.4
occ:1.00
|
F7
|
A:Q74320
|
0.0
|
11.4
|
1.0
|
C6
|
A:Q74320
|
1.3
|
11.4
|
1.0
|
C5
|
A:Q74320
|
2.4
|
11.9
|
1.0
|
C8
|
A:Q74320
|
2.4
|
10.4
|
1.0
|
S11
|
A:Q74320
|
3.1
|
10.6
|
1.0
|
CH2
|
A:TRP79
|
3.4
|
7.5
|
1.0
|
CD1
|
A:TRP111
|
3.5
|
8.2
|
1.0
|
SG
|
A:CYS80
|
3.5
|
9.4
|
1.0
|
CG
|
A:TRP111
|
3.5
|
7.3
|
1.0
|
CZ
|
A:PHE115
|
3.6
|
11.6
|
1.0
|
C2
|
A:Q74320
|
3.6
|
13.1
|
1.0
|
C9
|
A:Q74320
|
3.7
|
11.0
|
1.0
|
NE1
|
A:TRP111
|
3.8
|
7.5
|
1.0
|
CD2
|
A:TRP111
|
3.8
|
6.6
|
1.0
|
CZ2
|
A:TRP79
|
3.8
|
6.4
|
1.0
|
CE2
|
A:PHE122
|
3.9
|
13.9
|
1.0
|
CE2
|
A:PHE115
|
3.9
|
8.1
|
1.0
|
CE2
|
A:TRP111
|
4.0
|
7.5
|
1.0
|
CB
|
A:TRP111
|
4.0
|
7.4
|
1.0
|
C3
|
A:Q74320
|
4.1
|
12.8
|
1.0
|
CZ3
|
A:TRP79
|
4.1
|
7.1
|
1.0
|
OG1
|
A:THR113
|
4.2
|
8.9
|
1.0
|
CZ
|
A:PHE122
|
4.5
|
14.5
|
1.0
|
C12
|
A:Q74320
|
4.6
|
11.1
|
1.0
|
CE3
|
A:TRP111
|
4.6
|
7.4
|
1.0
|
CE1
|
A:PHE115
|
4.6
|
9.7
|
1.0
|
N10
|
A:Q74320
|
4.7
|
9.5
|
1.0
|
F1
|
A:Q74320
|
4.7
|
14.8
|
1.0
|
SG
|
A:CYS303
|
4.8
|
17.0
|
1.0
|
CB
|
A:CYS80
|
4.8
|
7.9
|
1.0
|
CD2
|
A:PHE122
|
4.9
|
11.6
|
1.0
|
CZ2
|
A:TRP111
|
4.9
|
9.2
|
1.0
|
CE2
|
A:TRP79
|
4.9
|
6.8
|
1.0
|
|
Reference:
M.C.Van Zandt,
B.Doan,
D.R.Sawicki,
J.Sredy,
A.D.Podjarny.
Discovery of [3-(4,5,7-Trifluoro-Benzothiazol-2-Ylmethyl)- Pyrrolo[2,3-B]Pyridin-1-Yl]Acetic Acids As Highly Potent and Selective Inhibitors of Aldose Reductase For Treatment of Chronic Diabetic Complications. Bioorg.Med.Chem.Lett. V. 19 2006 2009.
ISSN: ISSN 0960-894X
PubMed: 19250825
DOI: 10.1016/J.BMCL.2009.02.037
Page generated: Wed Jul 31 18:45:10 2024
|